Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma

BACKGROUND: Metastatic urothelial carcinoma (mUC) is a genomically diverse disease with known alterations in the mTOR pathway and tyrosine kinases including FGFR. We investigated the efficacy and safety of combination treatment with everolimus and pazopanib (E/P) in genomically profiled patients wit...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Cancer
Glavni autori: Bellmunt, Joaquim, Lalani, Aly-Khan A., Jacobus, Sussana, Wankowicz, Stephanie A., Polacek, Laura, Takeda, David Y., Harshman, Lauren C., Wagle, Nikhil, Moreno, Irene, Lundgren, Kevin, Bossé, Dominick, Van Allen, Eliezer M., Choueiri, Toni K., Rosenberg, Jonathan E.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2018
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6173710/
https://ncbi.nlm.nih.gov/pubmed/30220708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0261-0
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items